AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 94 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $238,267 | +26.7% | 528,897 | -18.5% | 0.00% | – |
| Q1 2023 | $188,108 | -35.3% | 648,648 | +0.4% | 0.00% | – |
| Q4 2022 | $290,615 | -46.4% | 645,954 | -37.4% | 0.00% | – |
| Q3 2022 | $542,000 | +0.4% | 1,032,665 | -3.5% | 0.00% | – |
| Q2 2022 | $540,000 | -92.0% | 1,069,602 | -63.4% | 0.00% | – |
| Q1 2022 | $6,719,000 | -52.8% | 2,921,810 | -2.6% | 0.00% | – |
| Q4 2021 | $14,243,000 | -40.0% | 2,998,479 | +0.5% | 0.00% | -100.0% |
| Q3 2021 | $23,723,000 | +9.8% | 2,983,895 | -3.9% | 0.00% | 0.0% |
| Q2 2021 | $21,605,000 | -18.6% | 3,103,879 | -7.4% | 0.00% | 0.0% |
| Q1 2021 | $26,534,000 | +4.1% | 3,350,312 | +3.4% | 0.00% | 0.0% |
| Q4 2020 | $25,498,000 | +15.0% | 3,239,975 | +3.6% | 0.00% | 0.0% |
| Q3 2020 | $22,176,000 | -25.5% | 3,127,765 | -2.8% | 0.00% | 0.0% |
| Q2 2020 | $29,755,000 | +234.4% | 3,216,824 | +68.5% | 0.00% | – |
| Q1 2020 | $8,897,000 | -39.4% | 1,908,970 | -0.7% | 0.00% | -100.0% |
| Q4 2019 | $14,686,000 | +0.4% | 1,922,215 | +1.0% | 0.00% | 0.0% |
| Q3 2019 | $14,629,000 | +15.2% | 1,902,520 | +2.6% | 0.00% | 0.0% |
| Q2 2019 | $12,704,000 | +5.9% | 1,854,713 | +24.4% | 0.00% | 0.0% |
| Q1 2019 | $11,998,000 | +22.8% | 1,490,392 | +14.3% | 0.00% | – |
| Q4 2018 | $9,768,000 | -0.8% | 1,304,062 | +26.7% | 0.00% | – |
| Q3 2018 | $9,847,000 | +13.1% | 1,028,996 | +25.1% | 0.00% | – |
| Q2 2018 | $8,703,000 | +3481.5% | 822,505 | +3257.3% | 0.00% | – |
| Q1 2018 | $243,000 | +104.2% | 24,499 | +11.6% | 0.00% | – |
| Q4 2017 | $119,000 | +30.8% | 21,951 | +19.1% | 0.00% | – |
| Q3 2017 | $91,000 | +26.4% | 18,428 | -2.1% | 0.00% | – |
| Q2 2017 | $72,000 | -36.3% | 18,832 | +24.3% | 0.00% | – |
| Q1 2017 | $113,000 | – | 15,155 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Yu Fan | 112,044 | $258,000 | 3.49% |
| Aisling Capital Management LP | 1,691,151 | $3,890,000 | 2.10% |
| Sio Capital Management, LLC | 871,101 | $2,004,000 | 0.66% |
| Bain Capital Life Sciences Investors, LLC | 2,847,689 | $6,550,000 | 0.64% |
| Samsara BioCapital, LLC | 883,720 | $2,033,000 | 0.51% |
| Ghost Tree Capital, LLC | 686,599 | $1,579,000 | 0.34% |
| Nantahala Capital Management | 3,200,593 | $7,361,000 | 0.33% |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $565,000 | 0.29% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 4,059,894 | $9,338,000 | 0.28% |
| Lion Point Capital, LP | 300,000 | $690,000 | 0.16% |